Meng Songdong
Professor
Institute of Microbiology
Chinese Academy of Sciences
China
Biography
He got Ph.D degree of Microbiology from Shenyang Institute of Applied Ecology of CAS in 1998. After graduation, he worked as a postdoctoral fellow and then instructor in Cancer Immunobiology Center of UT Southwestern Medical Center at Dallas. He came back to the CAS key lab in 2007 as a scholar of 'Bairen plan' of CAS. Dr. Meng’s current research involves studies of heat shock protein gp96 in innate and acquired immunity, therapeutic vaccine engineering against chronic Hepatitis B Virus (HBV) infection, and cancer targeted therapy.
Research Interest
We currently focus on: 1. Regulation of the immune response against HBV by heat shock protein, and therapeutic vaccine engineering for hepatitis B and cancer therapy 2. Targeted therapeutic approaches against HER2 and uPAR in breast cancer 3. Modulation of HBV replication by MicroRNAs
Publications
-
[3] Jun Hu, Yaxing Xu, Junli Hao, Saifeng Wang, Changfei Li, Songdong Meng. 2012. MiR-122 in hepatic function and liver diseases. Protein Cell, 3(5):364-71.
-
[2] Saifeng Wang, Lipeng Qiu, Xiaoli Yan, Wensong Jin, Yanzhong Wang, Lizhao Chen, Erjie Wu, Xin Ye, George F Gao, Fusheng Wang, Yu Chen, Zhongping Duan, Songdong Meng. 2012. Loss of MiR-122 Expression in Patients with Hepatitis B Enhances Hepatitis B Virus Replication through Cyclin G1 Modulated P53 Activity. Hepatology, 55：730-741.
-
[1] Junli Hao, Wensong Jin, Xinghui Li, Saifeng Wang, Xiaojun Zhang, Hongxia Fan, Changfei Li, Lizhao Chen, Bin Gao, Guangze Liu, Songdong Meng. 2012. IFN-α-induced miR-122 inhibition negatively affects the anti-HBV efficiency of IFN-α. Journal of Virology, Doi:10.1128/JVI.01710-12.
